Form 8-K SUNESIS PHARMACEUTICALS For: Mar 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil steadies on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Sunesis Pharmaceuticals (SNSS) Misses Q4 EPS by 1c
March 10, 2016 7:25 AM ESTSunesis Pharmaceuticals (NASDAQ: SNSS) reported Q4 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $670 thousand versus the consensus estimate of $700 thousand.
For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.
... More